Protocol Ledger

NCT07263776 · Phase III · ACTIVE NOT RECRUITING

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2

Interventional Phase III clinical trial protocol NCT07263776 sponsored by Capital Medical University in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-05 Enrollment: 692 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07263776
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)692 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07263776
Protocol FieldVerified Registry Value
NCT IdentifierNCT07263776
Consolidated Lead SponsorCapital Medical University
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment692 participants (ACTUAL)
Registered Start Date2025-12-05
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI